Light, Kathleen C, Agarwal, Neeraj, Iacob, Eli et al. · Psychoneuroendocrinology · 2013 · DOI
This study compared how certain genes are turned 'on' and 'off' differently in blood cells from people with ME/CFS, men with prostate cancer receiving hormone therapy, and healthy people. The researchers found that while both patient groups experience severe fatigue, they show different patterns of gene activity, suggesting that fatigue in these conditions may arise from different biological mechanisms. One gene related to calming the nervous system (DBI) was linked to fatigue severity in both patient groups, offering a potential target for future treatments.
Understanding that ME/CFS and similar fatigue states involve distinct genetic expression patterns could explain why treatments effective for one condition may not work for another. Identifying genes like DBI and P2RY1 as correlates of fatigue severity provides biological leads for developing targeted interventions. This work bridges immunology, metabolic dysfunction, and neuroendocrine pathways in ME/CFS pathogenesis.
This study does not prove that gene expression differences *cause* fatigue—only that they are associated with it. The cross-sectional design means causality cannot be determined, and correlation does not establish mechanism. The study also does not address whether gene expression changes are primary drivers of ME/CFS or secondary consequences of the illness.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →